Nec Corporation

Pfizer Corporation

Raqualia Pharma Inc.

Mitsubishi Heavy Industries Limited

Other

Sony Corporation

Requalia Pharma Inc.

Hiroki Koike

Yukari Matsumoto

Tohru Kimura

Daisuke Sato

Hideki Matsumoto

Shinobu Tsubota

Kazuya Yamaji

Tatsuya Yamagishi

Yoshiyuki Okumura

Kazunari Nakao

Yoshinobu Hashizume

Sachiko Mihara

Masako Hirota

Fumitaka Ito

Junichi Yamada

Hiroshi Nakamura

Seiji Nukui

Mikio Morita

Stephane Caron

Makoto Kawai

Takeshi Hanazawa

Kana Kon-I

Yasuhiro Katsu

Kiyoshi Kawamura

Tetsuya Ohtsuki

Masahide Takada

Sachiko Sakakibara

Tetsuya Otsuki

Hisoshi Nakamura

Kana Kon-i

Asato Morita

Chikara Uchida

Rodney William Stevens

[Solving Means] A resonance calculation program is configured to calculate an effective cross section including Step Sof setting a calculation point in the gray range in the resonance region; Step Sof calculating a neutron flux set at the calculation point and corresponding to a macroscopic cross section based on Method of Characteristics; Step Sof fitting a fitting equation to the calculated macroscopic cross section and the calculated neutron flux, and calculating first and second rational coefficients; Step Sof calculating a background cross section based on the first rational coefficient; Step Sof interpolating the effective cross section, with the background cross section used as an argument; Step Sof calculating the neutron flux based on the background cross section; and Step Sof calculating the effective cross section based on the effective cross section, the neutron flux, and the second rational coefficient obtained at the coefficient calculation step.

Resonance calculation program and analyzing apparatus

A nuclear-characteristic calculating program for calculating a nuclear characteristic of a fuel rod that contains nuclear fuel and burnable poison includes a first scattering model that can represent a simple scattering of the neutron and a second scattering model that can represent a complicated scattering of the neutron. The nuclear-characteristic calculating program includes step of calculating, when a burnup of the fuel rod is before a set burnup at which the burnable poison is considered to lose neutron absorption capability, the nuclear characteristic of the fuel rod by using the second scattering model, step of switching, when the burnup of the fuel rod is the set burnup, the scattering model from the second scattering model to the first scattering model, and step of calculating, after performing step of switching, the nuclear characteristic of the fuel rod by using the first scattering model.

Nuclear-characteristic calculating program and analyzing apparatus

[Problem to be Solved] To provide a resonance calculation program capable of evaluating a physical quantity such as an effective cross section in a radial direction of a circular region of a fuel rod by making a resonance calculation based on the equivalence principle. [Solution] A resonance calculation program for calculating an effective cross section by performing a resonance calculation based on an equivalence principle includes a radial-distribution calculation step Sof calculating a distribution of the effective cross section in a radial direction of a circular region by calculating the effective cross section defined by a predetermined calculation expression including a geographical coefficient for each of a plurality of annular regions while a neutron escape probability in a resonance region is expressed by a polynomial rational expression including the geographical coefficient serving as a factor representing geographical shapes of a plurality of annular regions that are circumferentially annular and that are obtained by radially dividing the circular region that is an axial cross section of a fuel rod at predetermined intervals.

This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein: R, R, R, R, A and E are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the method of treatment and the use, comprising such compounds for the treatment of a condition mediated by acid pump antagonistic activity such as, but not limited to, as gastrointestinal disease, gastroesophageal disease, gastroesophageal reflux disease (GERD), laryngopharyngeal reflux disease, peptic ulcer, gastric ulcer, duodenal ulcer, NSAID-induced ulcers, gastritis, infection of, dyspepsia, functional dyspepsia, Zolli&#x3c0;ger-Ellison syndrome, non-erosive reflux disease (NERD), visceral pain, cancer, heartburn, nausea, esophagitis, dysphagia, hypersalivation, airway disorders or asthma. 

Benzimidazole derivatives as selective acid pump inhibitors

This invention provides a compound of the formula (I): 

Substituted methyl aryl or heteroaryl amide compounds

This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein:A, B, X, R, R, R, R, R, R, Rand Rare each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by acid pump antagonistic activity such as, but not limited to, as gastrointestinal disease, gastroesophageal disease, gastroesophageal reflux disease (GERD), peptic ulcer, gastric ulcer, duodenal ulcer, NSAID-induced ulcers, gastritis, infection of, dyspepsia, functional dyspepsia, Zollinger-Ellison syndrome, non-erosive reflux disease (NERD), visceral pain, heartburn, nausea, esophagitis, dysphagia, hypersalivation, airway disorders or asthma.

Chromane substituted benzimidazole derivatives

This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein: A, B, X, R, R, R, R, Rand R, R, Rand Rare each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by acid pump antagonistic activity such as, but not limited to, as gastrointestinal disease, gastroesophageal disease, gastroesophageal reflux disease (GERD), peptic ulcer, gastric ulcer, duodenal ulcer, NSAID-induced ulcers, gastritis, infection of, dyspepsia, functional dyspepsia, Zollinger-Ellison syndrome, non-erosive reflux disease (NERD), visceral pain, heartburn, nausea, esophagitis, dysphagia, hypersalivation, airway disorders or asthma. 

Chromane substituted benzimidazole derivatives as acid pump antagonists

This invention provides a compound of the formula (I): wherein

This invention provides the compounds of formula (I): or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof, wherein Rand Rindependently represent a hydrogen atom or the like; Rrepresents a hydrogen atom, or the like; Rrepresents a hydrogen atom or the like; represents one of the following or the like; Rrepresents an aryl group having from 6 to 10 ring atoms or the like; X represents an oxygen atom, or the like; Y represents an oxygen atom or the like and n represents an integer 0, 1 or 2. These compounds have ORL1-receptor antagonist activity; and therefore, are useful to treat diseases or conditions such as pain, various CNS diseases etc.

Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists

This invention provides the compounds of formula (I): or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof, wherein Rand Rindependently represent a hydrogen atom or the like; These compounds have ORL1-receptor antagonist activity; and therefore, are useful to treat diseases or conditions such as pain, various CNS diseases etc.

Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists

The object of the present invention is to provide a semiconductor memory device wherein analog data signal potential read out from a memory cell to bit-line (bit-line read-out potential) can be measured precisely. In this invention, a sense part circuit blockdifferentially amplifies data signal occurring on one of a pair of bit-lines (for example, bit-line BLNk, BLTk) in a memory cell array, and reference signal occurring on another of the pair, and data is read out. Bit-lines BLN, BLT, -, BLNn, BLTn are connected to a reference potential setup circuit block. Reference potential setup circuitsets up potential assigned from outside of the device as potential of reference signal on bit-line. Bit-line read-out potential is indirectly obtained from the differential amplification result by controlling the reference potential with the reference potential setup circuit block

Semiconductor memory device and testing system and testing method

Pickup for disc player

A compound of the formula:or a pharmaceutically acceptable salt, ester or ether thereof, wherein Rthrough Rare independently hydrogen or the like; Xand Xare independently CHor the like; Ris hydrogen or the like; or Rand Rtaken together with three ring atoms of the quinoline ring separating said substituents form a heterocyclic ring; Rand Rare hydrogen or the like or these groups taken together form oxo; and the dotted line represents a single or double bond. These compounds are ligands for ORL-1 receptor and especially are antagonists for said receptor.

N-substituted spiropiperidine compounds as ligands for ORL-1 receptor

N-benzenesulfonyl L-proline compounds as bradykinin antagonists

2,3-substituted indole compounds as anti-inflammatory and analgesic agents

Growing community of inventors

Tokyo, Japan

Hiroki Koike